Review article · 9 Jun 2025
Conference abstractPublished 25 Aug 2015
Progression of Intravenous (IV) Lipopolysaccharide (LPS)-induced hypotension can be prevented by Intra-Cerebral Ventricular injection (ICV)
Albany College of Pharmacy and Health Sciences, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
We previously showed that progression of Intravenous (IV) Lipopolysaccharide (LPS)-induced hypotension can be prevented by Intra-Cerebral Ventricular injection (ICV) of the endocannabinoid type 1 (CB1) receptor inverse agonist/antagonist rimonabant. However, the role of brain CB1 receptors on LPS-induced pulmonary inflammation, an additional characteristic of endotoxemia, is not known. Hence, we tested the hypothesis that CB1 receptor antagonists in the brain will prevent lung inflammation in response to IV LPS. Male Sprague-Dawley rats received an initial ICV injection of rimonabant (500ng) or vehicle 5 minutes prior to IV injection of either LPS (5 mg/kg) or saline, followed by additional ICV injections at 1.5 and 3 hours post-LPS in the 4 hour treatment group.Lungs were removed at 30 minutes or 4 hours after IV LPS injection. The isolated-perfused lung was assessed for hemodynamics. Lung homgenates were assessed for TLR-4 signaling cascade markers and Ã?±7-nicotinic acetylcholine receptor activity. There was a decrease in Pulmonary Capillary Pressure (Ppc) and increases in the (Wet-Dry)/Dry lung weight ratio (WâÂ?Â?D/D) and (WâÂ?Â?D/D)/(Ppc) ratio in the ICV-vehicle/IV-LPS group at 4 hours. In lung homogenate of the same treatment group there were decreases in levels of IRAK1, IÃ?ºBÃ?±, phospho-RAF(Ser259) and phospho-Src (Tyr416) at 30 minutes and increases in IL-6, VCAM and Myeloperoxidase (MPO) at 4 hours. The ICV injection(s) of rimonabant attenuated or completely prevented the changes in hemodynamics, W-D/D, (W-D/D)/Ppc, IRAK1, IÃ?ºBÃ?±, pRAF (Ser259), pSrc (Tyr216), IL-6, VCAM and MPO in response to LPS injection. The data indicate that inhibition of the brain’s central CB1 activity modulates the initiation and progression of the lung inflammatory response to LPS.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Carlos Feleder”
